Abstract

Neopterin is a pyrazino-pyrimidine compound that belongs to the pteridine group. It is known to be a biochemical marker associated with cell-mediated immunity. It is produced by human monocytes/macrophages and dendritic cells from guanosine triphosphate (GTP) upon stimulation with interferon gamma (IFNγ), which is released by activated limphocytes Th. Neopterin is a very important clinic parameter, though the physiological role has not been exactly definited thus far. The level of neopterin reflects the stage of activation of the cellular immune system, which is important in the pathogenesis and progression of various diseases. Measuring its concentration in body fluids is used in many different areas of modern medicine, such as infectious disease, gastroenterology, transplantology and transfusiology, rheumatology or oncology. In neurological, cardio-vascular and autoimmune diseases, cell-mediated immunity is also activated, which is proved by the elevated level of this marker. Measurements of neopterin concentrations are also helpful in monitoring the therapy of patients infected with the HIV virus or treated by using immunomudulating therapy. As a result of measuring levels of neopterin in patients with neoplasms of digestive tract, increased concentration was proved, but it is not routinely used in everyday clinic practice.

References

• 1. Abu Shady M.M., Fathy H.A., Ali A., Youness E.R., Fathy G.A.: Associationof neopterin as a marker of immune system activation andjuvenile rheumatoid arthrits activity. J. Pediatr., 2015; 91: 352-357
  Google Scholar
• 2. Aleksandrova K., Chuang S.C., Boeing H., Zuo H., Tell G.S., PischonT., Jenab M., Bueno-de-Mesquita B., Vollset S.E., Midttun Ø., UelandP.M., Fedirko V., Johansson M., Weiderpass E., Severi G.. i wsp.: A prospectivestudy of the immune system activation biomarker neopterinand colorectal cancer risk. J. Natl. Cancer Inst., 2015; 107: pii: djv010
  Google Scholar
• 3. Asci A., Baydar T., Cetinkaya R., Dolgun A., Sahin G.: Evaluationof neopterin levels in patient undergoing hemodialysis. Hemodial. Int., 2010; 14: 240-246
  Google Scholar
• 4. Balázs C., Türke B., Vámos A.: Determination of serum neopterinlevels in patients with autoimmune thyroid diseases. Orv. Hetil.,2012; 153: 1127-1131
  Google Scholar
• 5. Bariş N., Erdoğan M., Sezer E., Saygili F, Mert Ozgönül A., TurganN., Ersöz B.: Alterations in L-arginine and inflammatory markers intype 2 diabetic patients with and without microalbuminuria. ActaDiabetol., 2009; 46: 309-316
  Google Scholar
• 6. Bartold M., Matowicka-Karna J.: Neopterin as a marker of inflammation.Diagn. Lab., 2015; 51: 153-156
  Google Scholar
• 7. Bertz L., Barani J., Gottsäter A., Nilsson P.M., Mattiasson I., LindbladB.: Are there differences of inflammatory bio-markers beetwendiabetic and non-diabetic patients with critical limb ischemia? Int.Angiol., 2006; 25: 370-377
  Google Scholar
• 8. Birk D., Gansauge F., Gansauge S., Schwarz A., Beger H.G.: Levelsof serum neopterin are increased in pancreatic cancer patientsand correlate with the prognosis. Eur. J. Med. Res., 1999; 4: 156-160
  Google Scholar
• 9. Carey B.S, Jain R., Adams L.C., Wong K.Y., Shaw S., Tse W.Y., KaminskiE.R.: Serum neopterin as an indicator of increased risk of renalallograft rejection. Transpl. Immunol., 2013; 28: 81-85
  Google Scholar
• 10. Ciećko-Michalska I., Fedak D., Mach T.: Neopterin in assessingthe activity of inflammatory bowel diseases: ulcerative colitis andCrohn’s disease. Przegl. Lek., 2010; 67: 1262-1265
  Google Scholar
• 11. Cincibuch J., Melichar B., Studentova H., Kapustova M., MalirovaE., Solichova D., Krcmova L., Kasparova M., Schneiderka P., JuranovaJ., Sramek V., Cwiertka K.: Serum neopterin, retinol and α-tocopherolin patients with the carcinoma of the esophagus. Pteridines, 2009;20: 49-53
  Google Scholar
• 12. Ciprandi G., De Amici M., Berardi L., Vignini M., Caimmi S.,Marseglia A., Marseglia G., Fuchs D.: Serum neopterin levels inspontaneous urticaria and atopic dermatitis. Clin. Exp. Dermatol.,2011; 36: 85-87
  Google Scholar
• 13. Datta S.P., Brown R.R., Borden E.C. Sondel P.M., Trump D.L.:Interferon and interleukin-2 induced changes in tryptophan andneopterin metabolism: possible markers for biologically effectivedoses. Proc. Am. Assoc. Cancer Res., 1987: 28: 338
  Google Scholar
• 14. Denz H., Fuchs D., Hausen A., Huber H., Nachbaur D., ReibneggerG., Thaler J., Werner E.R., Wachter H.: Value of urinary neopterinin the differential diagnosis of bacterial and viral infections. Klin.Wochenschr., 1990; 68: 218-222
  Google Scholar
• 15. Edwards S.W.: The respiratory burst: the generation of reactiveoxygen metabolites and their role in microbial killing. Biochemistryand physiology of the neutrophil. Cambridge University Press,1994; 149-158
  Google Scholar
• 16. Eisenhut M.: Neopterin in diagnosis and monitoring of infectiousdiseases. J. Biomark., 2013: 2013: 196432
  Google Scholar
• 17. Fuchs D., Avanzas P., Arroyo-Espliguero R., Jenny M., ConsuegraSanchezL., Kaski J.C.: The role of neopterin in atherogenesis and cardiovascularrisk assessment. Curr. Med. Chem., 2009; 16: 4644-4653
  Google Scholar
• 18. Fuchs D., Granditsch G., Hausen A., Reibnegger G., WachterH.: Urinary neopterin excretion in coeliac disease. Lancet, 1983;2: 463-464
  Google Scholar
• 19. Fuchs D., Norkrans G., Wejstal R., Reibnegger G., Weiss G., WeilandO., Schvarcz R., Fryden A,. Wachter H.: Changes of serum neopterin,β2-microglobulin and interferon g in patients with chronichepatitis C treated with interferon-α2b. Eur. J. Med., 1992; 1: 196-200
  Google Scholar
• 20. Garcia-Moll X., Coccolo F., Cole D., Kaski J.C.: Serum neopterinand complex stenosis morphology in patients with unstable angina.J. Am. Coll. Cardiol., 2000; 35: 956-962
  Google Scholar
• 21. Gomołka M., Niemczyk S., Paczek L.: Cytokiny; mechanizmyprowadzące do wzrostu produkcji cytokin u chorych hemodializowanych.Nefrol. Dial. Pol., 2003; 7: 114-117
  Google Scholar
• 22. Griffin D., Ward B., Jauregui E., Johnson RT, Vaisberg A.: Immuneactivation during measles: Interferon g and neopterin in plasmaand cerebrospinal fluid in complicated and uncomplicated disease.J. Infect. Dis., 1990; 161: 449-453
  Google Scholar
• 23. Gruengreiff K., Reinhold D., Ansorge S.: Serum concentrationsof sIL-2R, IL-6, TGF-β1, neopterin and zinc in chronic hepatitis Cpatients treated with interferon-α. Cytokine, 1999; 11: 1076-1080
  Google Scholar
• 24. Hagberg L., Dotevall L., Norkrans G., Larsson M., Wachter H.,Fuchs D.: Cerebrospinal fluid neopterin concentrations in centralnervous system infection. J. Infect. Dis., 1993; 168: 1285-1288
  Google Scholar
• 25. Hoffmann G., Schobersberger W., Frede S., Pelzer L., FandreyJ., Wachter H., Fuchs D., Grote J.: Neopterin activates transcriptionfactor nuclear factor-κB in vascular smooth muscle cells. FEBS Lett.,1996; 391: 181-184
  Google Scholar
• 26. Hoffmann G., Wirleitner B., Fuchs D.: Potential role of immunesystem activation-associated production of neopterin derivativesin humans. Inflamm. Res., 2003; 52: 313-321
  Google Scholar
• 27. Huber C., Batchelor J., Fuchs D., Hausen A., Lang A., Niederwieser D.,Reibnegger G., Swetly P., Troppmair J., Wachter H.: Immune response-associatedproduction of neopterin. Release from macrophages primarilyunder control of interferon-g. J. Exp. Med., 1984; 160: 310-316
  Google Scholar
• 28. Immanuel C., Swamy R., Kannapiran M., Vijayalakshmi S., SundaramV., Jagannath K, Paramasivan C.N.: Neopterin as a marker forcell-mediated immunity in patients with pulmonary tuberculosis.Int. J. Tuberc. Lung Dis.,1997; 1: 175-180
  Google Scholar
• 29. Inancli S.S., Caner S., Balkan F., Tam A.A., Guler G., Ersoy R., CakirB.: Urinary neopterin levels in patients with thyroid cancer. IndianJ. Otolaryngol. Head Neck Surg., 2014; 66: 302-308
  Google Scholar
• 30. Jassem J., Krzakowski M.: Nowotwory układu pokarmowego.Praktyczny przewodnik dla lekarzy. Via Medica, Gdańsk 2014
  Google Scholar
• 31. Jungraithmayr T.C., Reschke M., Grebe S.O., Lange H., RadsakK., Mueller T.F.: Assessment of cytomegalovirus infections usingneopterin and a new immunoblot. Clin. Chim. Acta, 2001; 310: 63-69
  Google Scholar
• 32. Keskin U., Ulubay M., Kurt Y.G, Fidan U., Koçyiğit Y.K., Honca T.,Aydin F.N., Ergün A.: Increased neopterin level and chitotriosidaseactivity in pregnant women with threatened preterm labor. J. Matern.Fetal Neonatal Med., 2015; 28: 1077-1081
  Google Scholar
• 33. Kronberger P., Weiss G., Tschmelitsch J., Fuchs D, Salzer G.M.,Wachter H., Reibnegger G.: Predictive value of urinary neopterin inpatients with lung cancer. Eur. J. Clin. Chem. Clin. Biochem., 1995;33: 831-837
  Google Scholar
• 34. Ledochowski M., Murr C., Widner B., Fuchs D.: Association betweeninsulin resistance, body mass and neopterin concentrations.Clin. Chim. Acta, 1999; 282: 115-123
  Google Scholar
• 35. Lhee H.Y., Kim H., Joo K.J., Jung S.S., Lee K.B.: The clinical significanceof serum and urinary neopterin levels in several renaldiseases. J. Korean Med. Sci., 2006; 21: 678-682
  Google Scholar
• 36. Lim K.L., Jones A.C., Brown N.S., Powell R.J.: Urine neopterinas a parameter of disease activity in patients with systemic lupuserythematosus: comparisons with serum sIL-2R and antibodies todsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3degradation products. Ann. Rheum. Dis., 1993; 52: 429-435
  Google Scholar
• 37. Maloney E.M., Brown L.M., Kurman C.C., Fuchs D., Nelson D.L.,Wachter H., Blattner W.A., Tollerud D.J.: Temporal variability in immunologicalparameters: peripheral blood mononuclear cell subsets,serum immunoglobulins and soluble markers of immune systemactivation. J. Clin. Lab. Anal., 1997; 11: 190-195
  Google Scholar
• 38. Manes G., Spada O.A., Rabitti P.G., Feola B., Misso S., Minerva A.,Uomo G.: Neopterin serum levels in pancreatic adenocarcinoma. Int.J. Pancreatol., 1999; 25: 31-37
  Google Scholar
• 39. Mangge H., Becker K., Fuchs D., Gostner J.M.: Antioxidants, inflammationand cardiovascular disease. World J. Cardiol., 2014; 6:462-477
  Google Scholar
• 40. Melichar B., Solichová D., Melicharová K.., Malírová E., CermanováM., Zadák Z.: Urinary neopterin in patients with advanced colorectalcarcinoma. Int. J. Biol. Markers, 2006; 21: 190-198
  Google Scholar
• 41. Melichar B., Solichová D., Svobodová I., Urbánek L., MelicharováK.: Urinary neopterin in patients with upper gastrointestinal, biliaryand pancreatic carcinomas. Pteridines, 2006; 17: 20-24
  Google Scholar
• 42. Muller T., Vogl M., Neumann M., Lange H., Grimm M., MüllerM.M.: Noninvasive monitoring using serum amyloid A and serumneopterin in cardiac transplantation. Clin. Chim. Acta, 1998; 276:63-74
  Google Scholar
• 43. Muller Kobold A.C., Kallenberg C.G., Tervaert J.W.: Monocyteactivation in patients with Wegener’s granulomatosis. Ann. Rheum.Dis., 1999; 58: 237-245
  Google Scholar
• 44. Murr C., Berchtold J., Norer B., Waldhart E., Wachter H., FuchsD.: Neopterin as a prognostic parameter in patients with squamous–cell carcinomas of the oral cavity. Int. J. Cancer, 1998; 79: 476-480
  Google Scholar
• 45. Murr C., Fuith L., Widner B., Wirleitner B., Baier-Bitterlich G.,Fuchs D.: Increased neopterin concentrations in patients with cancer:indicator of oxidative stress? Anticancer Res., 1991; 19: 1721-1728
  Google Scholar
• 46. Murr C., Widner, B., Wirleitner B., Fuchs D.: Neopterin as a markerfor immune system activation. Curr. Drug Metab., 2002; 3: 175-187
  Google Scholar
• 47. Nübling C.M., Chudy M., Volkers P., Lőwer J.: Neopterin levels duringthe early phase of human immunodeficiency virus, hepatitis Cvirus, or hepatitis B virus infection. Transfusion, 2006; 46: 1886-1891
  Google Scholar
• 48. Obada M., Helal M., Abd El Hakeem T., Abd El Hady H., Raouf A.:The value of serum neopterin as a potential marker of hepatocellularcarcinoma. Egyptian Liver J., 2013, 3: 97-102
  Google Scholar
• 49. Oda K., Arai T., Nagase M.: Increased serum and urinary neopterinin nephrotic syndrome indicate cell-mediated immune dysfunction.Am. J. Kidney Dis., 1999; 34: 611-617
  Google Scholar
• 50. Okumura A., Takemoto K.., Ozaki T.: Serum β-2-microglobulinand neopterin levels in children with febrile illness: their relationto influenza and febrile seizures. J. Pediatr. Neurol., 2003; 1: 35-38
  Google Scholar
• 51. Pagel H., Fandrey J., Schobersberger W., Fuchs D., Jelkmann W.:Effects of neopterin and 7,8-dihydroneopterin on hypoxia-inducedrenal erythropoietin production. Eur. J. Haematol., 1999; 62: 341-345
  Google Scholar
• 52. Park I.S., Lee Y.S., Kim J.C., Hwang S.G.: Serum neopterin levelsin ovarian tumors. Int. J. Gynaecol. Obstet., 1995; 51: 229-234
  Google Scholar
• 53. Parker D.C., Mielke M.M., Yu Q., Rosenberg P.B., Jain A., LyketsosC.G., Fedarko N.S., Oh E.S.: Plasma neopterin level as a marker of peripheralimmune activation in amnestic mild cognitive impairmentand Alzheimer’s disease. Int. J. Geriatr. Psychiatry, 2013; 28: 149-154
  Google Scholar
• 54. Reibnegger G.J., Bichler A.H., Dapunt O., Fuchs D.N., Fuith L.C.,Hausen A., Hetzel H.M., Lutz H., Werner E.R., Wachter H.: Neopterinas a prognostic indicator in patients with carcinoma of the uterinecervix. Cancer Res., 1986; 46: 950-955
  Google Scholar
• 55. Sahin T.T., Yuksel O., Girgin G., Sipahi H., Dikmen K., Azili C.,Taneri F., Baydar T.: Is neopterin level a predictive and differentialbiomarker in patients with thyroid disorders? J. Endocrinol. Invest.,2009; 32: 147-149
  Google Scholar
• 56. Samsonov M.Y., Tilz G.P., Egorova O., Reibnegger G., BalabanovaR.M., Nassonov E.L., Nassonova V.A., Wachter H., Fuchs D.: Serum solublemarkers of immune activation and disease activity in systemiclupus erythematosus. Lupus, 1995; 4: 29-32
  Google Scholar
• 57. Schumacher M., Halwachs G., Tatzber F., Fruhwald F.M., ZweikerR., Watzinger N., Eber B., Wilders-Truschnig M., Esterbauer H., KleinW.: Increased neopterin in patients with chronic and acute coronarysyndromes. J. Am. Coll. Cardiol., 1997; 30, 703-707
  Google Scholar
• 58. Shumakov V.I., Shevchenko O.P., Kazakov E.N., Orlova O.V., GureevS.V., Makarova L.V.: Prognostic value of C-reactive protein andneopterin in autologous bone marrow cells transplantation. Kardiologiia,2006; 46: 19-26
  Google Scholar
• 59. Stoy N., Mackay G.M., Forrest C.M., Christofides J., Egerton M.,Stone T.W., Darlington L.G.: Tryptophan metabolism and oxidativestress in patients with Huntington’s disease. J. Neurochem., 2005;93: 611-623
  Google Scholar
• 60. Sucher R., Schroecksnadel K., Weiss G., Margreiter R., Fuchs D.,Brandacher G.: Neopterin, a prognostic marker in human malignancies.Cancer Lett., 2010; 287: 13-22
  Google Scholar
• 61. Sugioka K., Naruko T., Matsumura Y., Shirai N., Hozumi T., Yoshiyama M., Ueda M.: Neopterin and atherosclerotic plaque instabilityin coronary and carotid arteries. J. Atheroscler. Thromb., 2010;17: 1115-1121
  Google Scholar
• 62. Sznarkowska A., Olszewski R., Zawacka-Pankau J.: Pharmacologicalactivation of tumor suppressor, wild-type p53 as a promisingstrategy to fight cancer. Postępy Hig. Med. Dośw., 2010; 64: 396-407
  Google Scholar
• 63. te Witt R., van Wolfswinkel M.E., Petit P.L., van Hellemond J.J.,Koelewijn R., van Belkum A., van Genderen P.J.: Neopterin and procalcitoninare suitable biomarkers for exclusion of severe Plasmodiumfalciparum disease at the initial clinical assessment of travellers withimported malaria. Malar. J., 2010; 9: 255
  Google Scholar
• 64. Tomšíková H., Solich P., Nováková L.: Sample preparation andUHPLC-FD analysis of pteridines in human urine. J. Pharm. Biomed.Anal., 2014; 95: 265-272
  Google Scholar
• 65. Tsuda Y., Fukuda A., Kobayashi H., Itou D., Yoshimoto S., IwataK., Hanafusa T.: Serum neopterin as a marker for screening of hepatocellularcarcinoma. Pteridines, 2004; 15: 161-169
  Google Scholar
• 66. Turgut T., Akbulut H., Deveci F., Kacar C., Muz M.H.: Serum interleukin-2and neopterin levels as useful markers for treatment of activepulmonary tuberculosis. Tohoku J. Exp. Med., 2006; 209: 321-328
  Google Scholar
• 67. Unal B., Kocer B., Altun B., Surmeli S.,Aksaray S., Balci M., OzluB., Cengiz O.: Serum neopterin as a prognostic indicator in patientswith gastric carcinoma. J. Invest. Surg., 2009; 22: 419-425
  Google Scholar
• 68. Überall F., Werner-Felmayer G., Schubert C., Grunicke H.H.,Wachter H., Fuchs D.: Neopterin derivatives together with cyclicguanosine monophosphate induce c-fos gene expression. FEBS Lett.,1994; 352: 11-14
  Google Scholar
• 69. Vrecko K., Staedtler P., Mischak I., Maresch L., Reibnegger G.:Periodontitis and concentrations of the cellular immune activationmarker neopterin in saliva and urine. Clin. Chim. Acta, 1997;268: 31-40
  Google Scholar
• 70. Wachter H., Hausen A., Grassmayr K.: Erhöhte Ausscheidungvon Neopterin im Harn von Patienten mit malignen Tumoren undmit Viruserkrankungen. Hoppe-Seyler’s Z. Physiol. Chem.,1979; 360:1957-1960
  Google Scholar
• 71. Wede I., Altindag Z., Widner B., Wahter H., Fuchs D.: Inhibitionof xanthine oxidase by pterins. Free Radic Res., 1998; 29: 331-338
  Google Scholar
• 72. Weiss G., Fuchs D., Hausen A., Reibnegger G., Werner E.R., Werner-FelmayerG., Semenitz E., Dierich M.P., Wachter H.: Neopterinmodulates toxicity mediated by reactive oxygen and chloride species.FEBS Lett., 1993; 321: 89-92
  Google Scholar
• 73. Weiss M.F., Rodby R.A., Justice A.C., Hricik D.E.: Free pentosidineand neopterin as markers of progression rate in diabetic nephropathy.Kidney Int., 1998; 54: 193-202
  Google Scholar
• 74. Werner-Felmayer G., Werner E.R., Fuchs D., Hausen A., ReibneggerG., Wachter H.: Tumour necrosis factor-α and lipopolysaccharideenhance interferon-induced tryptophan degradation andpteridine synthesis in human cells. Biol. Chem. Hoppe Seyler, 1989;370: 1063-1069
  Google Scholar
• 75. Wietlicka I., Korzeniowska K., Bogdański P., Kazmierczak M.,Chmara E., Musialik K., Jabłecka A.: The assessment of neopterinconcentration in patients with heart failure. Pol. Merkur. Lekarski,2010; 28: 256-259
  Google Scholar
• 76. Wietlicka I., Korzeniowska K., Jabłecka A.: Neopteryna. FarmacjaWspółczesna, 2008; 1: 241-247
  Google Scholar
• 77. Wirleitner B., Schroecksnadel K., Winkler C., Fuchs D.: Neopterinin HIV-1 infection. Mol. Immunol., 2005; 42: 183-194
  Google Scholar
• 78. Yanchun L., Zhidong H.: Significance of humoral neopterin inclinical diagnostics and prognosis. J. Med. Coll. PLA, 2011; 26: 45-51
  Google Scholar
• 79. Yildirim Y., Gunel N., Coskun U., Pasaoglu H., Aslan S., Cetin A.:Serum neopterin levels in patients with breast cancer. Med Oncol.,2008; 25: 403-407
  Google Scholar
• 80. Zaknun D., Weiss G., Glatzl J., Wachter H., Fuchs D.: Neopterinlevels during acute rubella in children. Clin. Infect. Dis., 1993; 17:521-522
  Google Scholar
• 81. Zeng X,. Zhang G., Yang B., Zhang B., Zhang L., Ni Y., Liu C., LuoY.: Neopterin as a predictor of functional outcome and mortalityin Chinese patients with acute ischemic stroke. Mol. Neurobiol.,2016; 53: 3939-3947
  Google Scholar
• 82. Zhao H.X., Yin S.S., Fan J.G.: High plasma neopterin levels inChinese children with autism spectrum disorders. Int. J. Dev. Neurosci.,2015; 41: 92-97
  Google Scholar
• 83. Zheng B., Cao K., Chan C., Choi J.W., Leung W., Leung M., DuanZ.H., Gao Y., Wang M., Di B., Hollidt J.M., Bergmann A., Lehmann M.,Renneberg I., Tam J.S. i wsp.: Serum neopterin for early assessmentof severity of severe acute respiratory syndrome. Clin. Immunol.,2005; 116: 18-26
  Google Scholar

Full text